Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB. Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. J Clin Oncol. 2012 Jun 4. (Epub ahead of print)

Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M, Saltz LB. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 2012 Mar 21. (Epub ahead of print)

Iyer G, Morris M, Rathkopf D, Slovin S, Steers M, Larson S, Schwartz L, Curley T, Delacruz A, Ye Q, Heller G, Egorin M, Ivy PS, Rosen N, Scher H, Solit D. A Phase I Trial of Docetaxel and Pulse-Dose 17-Allylamino-17- Demethoxygeldanamyci n in Adult Patients with Solid Tumors. Cancer Chemother Pharmacol. 2011 Nov 29 (Epub ahead of print).

Poulikakos P, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Bjoern Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

Hanrahan AJ, Schultz N, Westfal ML, Sakr, RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She Q, Aghajanian C, King TA, DeStanchina E, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB. Genomic complexity and AKT-dependence in serous ovarian cancer. Cancer Discovery 2011 Nov 3 (Epub ahead of print).

Bass A, Lawrence M, Brace L, Ramos A, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak R, Stransky N, Boutin A, Barretina J, Solit D, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang D, Signoretti S, Kaelin W, Spardy N, Hahn W, Hoshida Y, Ogino S, DePinho R, Chin L, Garraway L, Fuchs C, Baselga J, Tabernero J, Gabriel S, Lander E, Getz G, Meyerson M. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genetics, 2011 Sep 4 (Epub ahead of print).

Xing F, Persaud Y, Pratilas C, Taylor B, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit D. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene 2011 Jul 4 (Epub ahead of print).

Al-Ahmadie H, Iyer G, Janakiraman M, Lin O, Tickoo S, Fine S, Gopalan A, Chen Y, Balar A, Riches J, Bochner B, Dalbagni G, Bajorin D, Reuter V, Milowsky M, Solit D. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphologic subtype of high-grade urothelial carcinoma. J Pathol 224(2):270-9, 2011.

Reidy D, Vakiani E, Fakih M, Wasif Saif M, Hecht R, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Solit D, Saltz L. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010; 28(27):4240-6.

Halilovic E, She QB, Ye Q, Pagliarinis R Sellers W, Solit D, Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010; 70(7):6804-14. 

Joseph E, Pratilas C, Poulikakos P, Tadi M, Wang W, Taylor B, Persaud Y, Halilovic E, Xing F, Viale A, Tsai J, Bollag G, Solit D*, Rosen N*. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107(33):14903-8. *The last two authors contributed equally to this study. 

She Q, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit D, Rosen N. 4E-BP1 Is A Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell 2010; 18(1):39-51.

Janakiraman M, Vakiani E, Zeng Z, Pratilas C, Taylor B, Chitale D, Halilovic E, Ricarte-Filho J, Persaud Y, Levine D, Fagin J, Lash A, Jhanwar S, Mariadason J, Ladanyi M, Saltz L, Heguy A, Paty P, Solit D. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70(14).

Pratilas C, Taylor B, Ye Q, Viale A, Sander C, Solit D, Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009;106(11):4519-24.

Pratilas C, Hanrahan A, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Sawai A, Janakiraman M, Taylor B, Pao W, Ladanyi M, Gazdar A, Rosen N, Solit D. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68(22):9375-9383.

Sawai A, Chandarlapaty S, Gonen M, Greulich H, Ye Q, Arteaga C, Sellers W, Rosen N, Solit D. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008; 68(2):589-596.

Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit D. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER- kinase dependent cancers. Clin Cancer Res 2008; 14(1):240-8.

Solit D, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-Leopold J, Larson S, Rosen N. 3'- deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007; 67(23):11463-9.

O’Reilly K, Rojo F, She Q, Solit D, Mills G, Smith D, Lane H, Hofmann F, Hicklin D, Ludwig D, Baselga J, Rosen N. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Res 2006;66(3):1500-8.

Grbovic O, Basso A, Sawai A, Ye Q, Friedlander P, Osman I, Solit D, Rosen N. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006; 103:57-62.

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A, Ye Q, Lobo J, She Y, Osman I, Golub T, Sebolt-Leopold J, Sellers W, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439(7074):358-62.

She Q, Solit D, Ye Q, O’Reilly K, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8:287-297.